Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Price Performance

Shares of NASDAQ:TRVN opened at $1.32 on Wednesday. The company’s fifty day moving average price is $1.66 and its 200 day moving average price is $2.23. Trevena has a 12 month low of $1.13 and a 12 month high of $13.75. The firm has a market capitalization of $1.14 million, a P/E ratio of -0.03 and a beta of 1.05.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.